FGF-21

FGF-21 Informations sur la molécule

Nom anglais	Fibroblast growth factor 21	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	10	Alias de la cible	FGF21
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Fibroblast growth factor 21
Alias de la cible	FGF21
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	10
Phase de R&D la plus avancée	Phase 3 Clinical

FGF-21 Liste de produits

Attribut
Protein (2)Cell (1)Kits (1)
Bibliothèque de produits
En ligne (4)
Espèces
Human (4)
Étiquette
His Tag (1)His Tag & Avi Tag (1)- (2)
Marqueur
Unconjugated (1)Biotin-labeled (1)- (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT FG1-H5243	Human	HEK293	Human FGF-21 Protein, His Tag (SPR verified)	Ajouter au panier
CEA-B268	Human	-	Human FGF-21 ELISA Kit	Ajouter au panier
CHEK-ATF163	Human	HEK293	Human FGF-21 (Luc) HEK293 Reporter Cell	Ajouter au panier
FG1-H82Q3	Human	HEK293	Biotinylated Human FGF-21 Protein, His,Avitag™	Ajouter au panier

Quantité totale4

FGF-21Contexte de la molécule

Fibroblast growth factor 21 (FGF21), which stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression. FGF21 has been shown to protect animals from diet-induced obesity when overexpressed in transgenic mice. It also lowers blood glucose and triglyceride levels when administered to diabetic rodents, suggesting it may exhibit the therapeutic characteristics necessary for effective treatment of diabetes. Treatment of animals with FGF21 results in increased energy expenditure, fat utilisation and lipid excretion. FGF21 is most abundantly expressed in the liver, and also expressed in the thymus at lower levels.

FGF-21Alias de la molécule

FGF-21, FGF21

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Pegozafermin	BIO89-100; TEV-47948	Phase 3 Clinical	Teva Pharmaceutical Industries Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
Efimosfermin alfa	LLF-580; BOS-580; GSK-6519754	Phase 3 Clinical	Novartis Pharma Ag	Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
Efruxifermin	AKR-001; AMG-876; EFX; Fc-FGF21(RGE)	Phase 3 Clinical	Amgen Inc	Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
MWN-105	MWN-105	Phase 2 Clinical	Shanghai Minwei Biotechnology Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	Details
TQA-2225	AP-025; TQA2225; TQA-2225	Phase 2 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
HEC-88473	HEC-88473; HEC88473; APL-18881	Phase 2 Clinical	Dongguan Hec Taigen Biopharmaceuticals Co Ltd	Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
B-1344	B-1344	Phase 1 Clinical	Tasly Biomedical Co Ltd	Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
DMR-2301	DMR-2301; DMR2301	Phase 1 Clinical	Shanghai Duomirui Biotechnology Co Ltd	Metabolic Dysfunction-Associated Steatotic Liver Disease	Details
ZT-003	ZT003; ZT-003	Phase 1 Clinical	Beijing QL Biopharmaceutical Co Ltd	Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity	Details
AP-026	TQA2226; AP026; AP-026; TQA-2226	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight	Details